Nuritas™ Raises $45 Million To Scale Its Peptide Discovery Platform And Expand Globally
Nuritas, a biotechnology company revolutionizing the discovery and development of plant-based bioactive peptides, has closed a $45 million USD Series B funding round. The investment, led by Chicago-based Cleveland Avenue, LLC, includes Grosvenor’s Wheatsheaf Group, the European Circular Bioeconomy Fund (ECBF), Singapore-based Vertex Holdings, Nutresa Ventures/ Veronorte and CJ. Cultivian Sandbox Ventures and VisVires New Protein, who led previous rounds, also participated. Other early investors include U2’s Bono and The Edge, Salesforce CEO Marc Benioff and Ali Partovi. Total funding to date is $75 million USD.
The new funding will accelerate Nuritas’ global expansion and support its mission to unlock the power of nature to make many of the products we consume daily healthier, safer and more sustainable. Randall Lewis, managing director of Cleveland Avenue, LLC and Stephan Dolezalek, executive director of Grosvenor’s Wheatsheaf Group will join Nuritas’ Board of Directors.
Nuritas has also grown its Advisory Board with Indra Nooyi, former CEO of Pepsico and board member at Amazon, Joerg Ohle of Bayer’s Global Consumer Health division, and Bruce German, professor and chemist of food science and technology at the University of California, Davis and the director of its Foods for Health Institute.
“It has been a landmark year, resulting in the expansion of our peptide portfolio, growing the commercial team and developing key global partnerships,” said Dr. Nora Khaldi, founder and CEO of Nuritas. “Our new investors bring a wealth of invaluable expertise, and this latest round will help to build our US headquarters, continue to expand our team, scale our platform to discover more life-changing ingredients and accelerate our route to market.”
Nuritas has established the world’s largest peptide knowledge base. Peptides are smaller versions of proteins with the same nutritional power, but with added highly specific benefits. Many of these are highly valuable to humans but have not yet been harnessed for their full potential. Nuritas uses a proprietary AI and genomics platform called Nπϕ™ (Nuritas Peptide Finder) to rapidly analyze billions of hidden peptides in plants and natural food sources to predict and identify how they impact specific health areas, molecular pathways or receptors. The Nuritas platform has been shown to identify and develop new bioactives 10 times faster and with much greater accuracy than traditional discovery methods, significantly reducing costs.
“Nuritas is led by a talented team and its AI-powered, peptide discovery platform Nπϕ is a novel and proprietary platform technology that offers unprecedented value to the future of our health and our planet,” said Lewis. ”Cleveland Avenue is pleased to be a part of the company’s ongoing growth and we anticipate Nuritas will become a global ingredient powerhouse and a partner of choice for companies around the world.”
Nπϕ has attracted high-profile partnerships and customers, including Nestle, Mars, Sumitomo Corporation and Pharmavite. The company’s science-proven bioactive peptides are unlocked from plants and natural food sources, with applications across functional foods, supplements, medical food, cosmetics and food technology.
Stephan Dolezalek, executive director, Grosvernor’s Wheatsheaf Group, said: “We are pleased to join Nuritas as it prepares to launch new consumer products alongside an impressive pipeline of novel molecules and ongoing partnerships with global consumer product businesses. Nuritas’ capabilities match Wheatsheaf’s mission to re-shape how food is produced and consumed while benefiting the environment and human health.”
Nuritas introduced PeptAide™ 4, the world’s first AI-discovered ingredient in rice (together with BASF) and recently launched two clinically proven ingredients: PeptiYouth™, discovered from peas and supporting skin health, and PeptiStrong™, discovered in fava-beans and supporting muscle health. Both are being formulated for early 2022 market entry.
About Cleveland Avenue, LLC
Founded by Don Thompson, the former President and CEO of McDonald’s Corporation, Cleveland Avenue is a venture capital firm that invests in food and beverage brands, and technology companies that positively disrupt large and growing markets. Learn more about Cleveland Avenue at clevelandavenue.com and follow us on Twitter, LinkedIn, and Instagram.
About Nuritas
Nuritas is revolutionizing the discovery of novel, natural and scientifically proven bioactive ingredients that enable their partners to create better or new product solutions for their customers. The company’s disruptive computational approach to discovery uses artificial intelligence, deep learning, and genomics to rapidly and efficiently predict and then unlock the most health-benefiting components hidden within plants and natural food sources, called peptides. Nuritas has since established the world’s largest peptide knowledge base. Through its discoveries, Nuritas wants to firstly manage and improve human health and secondly help make our food system more sustainable by replacing current unwanted ingredients and molecules with more natural and sustainable ones. Find us on Twitter, LinkedIn or via our website at www.nuritas.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005401/en/
Contact information
Nuritas Press Contacts
Lizi Sprague
SonguePR for Nuritas
nuritas@songuepr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zayed Sustainability Prize Opens Global Call for Submissions for 2027 Cycle26.1.2026 17:25:00 EET | Press release
The Zayed Sustainability Prize, an affiliate of Erth Zayed Philanthropies and the UAE’s pioneering global award for sustainability and humanitarian innovation, has opened submissions for its 2027 cycle. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126912976/en/ Winners of the 2026 Zayed Sustainability Prize (Photo: AETOSWire) The Prize carries forward the vision and legacy of the UAE’s founding father, Sheikh Zayed bin Sultan Al Nahyan, by supporting those advancing a more inclusive and sustainable world. Now in its 18th year and with a total of US $7.2 million in funds, the Prize invites small and medium enterprises, nonprofit organisations, and high schools to submit innovative solutions across six categories: Health, Food, Energy, Water, Climate Action, and Global High Schools. Commenting on the launch of the 2027 submissions cycle, H.E. Dr. Sultan Ahmed Al Jaber, UAE Minister of Industry and Advanced Technology and
2026 Japan Prize: Two U.S. Scientists and One Japanese Scientist Awarded26.1.2026 16:00:00 EET | Press release
The Japan Prize Foundation announced the winners of the 2026 Japan Prize at 1:00 p.m. on 21 January 2026. Prof. Cynthia Dwork (USA) has been awarded the Japan Prize in the field of Electronics, Information, and Communication. Prof. Shizuo Akira (Japan) and Prof. Zhijian "James" Chen (USA) have been awarded the Japan Prize in the field of Life Sciences. For this year’s Japan Prize, Prof. Dwork is being recognized for her Contribution to leading research for building an ethical digital society, including differential privacy and fairness. Prof. Akira and Prof. Chen are being recognized for their Discovery of the nucleic acid sensing mechanism by the innate immune system. For the 2026 Japan Prize, the Foundation asked approximately 16,000 prominent scientists and engineers from around the world to nominate researchers working in this year’s fields. We received 107 nominations for the field of Electronics, Information, and Communication, and 185 nominations for the field of Life Sciences.
Uzbekistan, the Engine of Central Asia: GDP Above USD 145 Billion and Exports Rising to USD 33.4 Billion – Embassy of the Republic of Uzbekistan in Italy26.1.2026 15:31:00 EET | Press release
With a GDP exceeding USD 145 billion, exports of USD 33.4 billion up 23 percent, and gold reserves surpassing USD 60 billion, Uzbekistan enters 2026 with solid and steadily strengthening macroeconomic indicators. The Embassy of the Republic of Uzbekistan in Italy claims that the climate of confidence, reaffirmed in the State of the Nation Address delivered on 26 December by President Shavkat Mirziyoyev, is reflected in international trade data: total foreign investment has reached USD 43.1 billion, equal to 31.9 percent of GDP. This trajectory has also contributed to an improvement in the country’s sovereign rating, upgraded to BB by the leading international rating agencies. For the current year, the Government forecasts economic growth of 6.6 percent, with GDP estimated at USD 167 billion. A total of 782 new industrial and infrastructure projects will be launched, with an overall value of USD 52 billion, including 228 large production facilities as early as next year. The focus will
Novaliq Receives FDA IND Clearance to Advance NOV05 in a Phase II Clinical Trial in Non-infectious Anterior Uveitis26.1.2026 15:00:00 EET | Press release
Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique water-free EyeSol® drug category, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NOV05, the company’s first IND for treating inner-eye diseases. NOV05, tacrolimus ophthalmic solution in EyeSol®, is a unique, steroid-free topical anti-inflammatory treatment. The IND clearance enables initiation of the EYETAC Phase II clinical trial in patients with non-infectious anterior uveitis (NIAU). Anterior uveitis is an inflammation of the inner eye including the iris and ciliary body, that typically causes a red, painful, light‑sensitive eye and can lead to vision loss if not treated promptly. NIAU represents 67-90% of uveitis cases in the developed world.1 To treat uveitis a drug must reach the uveal tract inside the eye. Current treatment choices are limited to corticosteroid eye drops and, if insuffic
Lucend, Formerly Coolgradient, Raises $3.3M to Bring Transparent AI to Data Centers to Increase Uptime and Reliability While Maximizing Efficiency26.1.2026 15:00:00 EET | Press release
Lucend today announced that it is bringing its transparent data center optimization to the U.S. market, helping enterprises illuminate complex operational environments and empowering data center operators, innovation officers, and sustainability officers with the intelligence they need to act with trust, accuracy, and confidence. Lucend’s Transparent AI platform connects to existing infrastructure, no new hardware required, to transform static systems into adaptive, self-learning environments. The software takes existing sensor data to see connections across 300 billion sensor readings. Lucend’s AI analyzes billions of data points daily and provides prescriptive recommendations. The intelligence that Lucend’s platform delivers “shows its work,” empowering operators and delivering verifiable impact across enterprise environments that demand both performance and trust. “Lucend’s Transparent AI platform analyzes billions of data points daily and provides prescriptive recommendations that
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom